170 related articles for article (PubMed ID: 15054809)
1. The Mexican schedule to conduct allogeneic stem cell transplantation is related to a low risk of cytomegalovirus reactivation and disease.
Ruiz-Argüelles GJ; Rangel JD; Ponce-de-León S; González-Déctor L; Reyes-Núñez V; Garcés-Eisele J
Am J Hematol; 2004 Apr; 75(4):200-4. PubMed ID: 15054809
[TBL] [Abstract][Full Text] [Related]
2. Risk for cytomegalovirus infection following reduced intensity allogeneic stem cell transplantation.
Nachbaur D; Larcher C; Kircher B; Eibl G; Nussbaumer W; Gunsilius E; Haun M; Grünewald K; Gastl G
Ann Hematol; 2003 Oct; 82(10):621-7. PubMed ID: 12920570
[TBL] [Abstract][Full Text] [Related]
3. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT).
Zikos P; Van Lint MT; Lamparelli T; Gualandi F; Occhini D; Mordini N; Berisso G; Bregante S; Bacigalupo A
Haematologica; 1998 Feb; 83(2):132-7. PubMed ID: 9549924
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience.
Piñana JL; Martino R; Barba P; Margall N; Roig MC; Valcárcel D; Sierra J; Rabella N
Bone Marrow Transplant; 2010 Mar; 45(3):534-42. PubMed ID: 19668235
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus antigenemia and outcomes of patients undergoing allogeneic peripheral blood stem cell transplantation: effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovir treatment.
Hazar V; Ugur A; Colak D; Saba R; Tezcan G; Kupesiz A; Karadogan I; Gultekin M; Yesilipek A; Undar L
Jpn J Infect Dis; 2006 Aug; 59(4):216-21. PubMed ID: 16936338
[TBL] [Abstract][Full Text] [Related]
7. Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation.
Shigematsu A; Yasumoto A; Yamamoto S; Sugita J; Kondo T; Onozawa M; Kahata K; Endo T; Ota S; Sato N; Takahata M; Okada K; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
Biol Blood Marrow Transplant; 2009 Jun; 15(6):679-85. PubMed ID: 19450752
[TBL] [Abstract][Full Text] [Related]
8. Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure.
Nakamura R; Battiwalla M; Solomon S; Follmann D; Chakrabarti S; Cortez K; Hensel N; Childs R; Barrett AJ
Biol Blood Marrow Transplant; 2004 Jan; 10(1):49-57. PubMed ID: 14752779
[TBL] [Abstract][Full Text] [Related]
9. Fludarabine-based reduced intensity conditioning transplants have a higher incidence of cytomegalovirus reactivation compared with myeloablative transplants.
George B; Kerridge I; Gilroy N; Huang G; Hertzberg M; Gottlieb D; Bradstock K
Bone Marrow Transplant; 2010 May; 45(5):849-55. PubMed ID: 19915635
[TBL] [Abstract][Full Text] [Related]
10. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS
Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
[TBL] [Abstract][Full Text] [Related]
11. Increased levels of tumor necrosis factor alpha are associated with an increased risk of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.
Reddy V; Meier-Kriesche HU; Greene S; Schold JD; Wingard JR
Biol Blood Marrow Transplant; 2005 Sep; 11(9):698-705. PubMed ID: 16125640
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab.
Lamba R; Carrum G; Myers GD; Bollard CM; Krance RA; Heslop HE; Brenner MK; Popat U
Bone Marrow Transplant; 2005 Nov; 36(9):797-802. PubMed ID: 16151431
[TBL] [Abstract][Full Text] [Related]
13. A risk score for early cytomegalovirus reactivation after allogeneic stem cell transplantation identifies low-, intermediate-, and high-risk groups: reactivation risk is increased by graft-versus-host disease only in the intermediate-risk group.
George B; Kerridge IH; Gilroy N; Huang G; Hertzberg MS; Bradstock KF; Gottlieb DJ
Transpl Infect Dis; 2012 Apr; 14(2):141-8. PubMed ID: 22283838
[TBL] [Abstract][Full Text] [Related]
14. Interferon gamma 13-CA-repeat homozygous genotype and a low proportion of CD4(+) lymphocytes are independent risk factors for cytomegalovirus reactivation with a high number of copies in hematopoietic stem cell transplantation recipients.
Jaskula E; Dlubek D; Duda D; Bogunia-Kubik K; Mlynarczewska A; Lange A
Biol Blood Marrow Transplant; 2009 Oct; 15(10):1296-305. PubMed ID: 19747638
[TBL] [Abstract][Full Text] [Related]
15. Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogeneic stem cell transplantation.
Avetisyan G; Larsson K; Aschan J; Nilsson C; Hassan M; Ljungman P
Bone Marrow Transplant; 2006 Nov; 38(10):687-92. PubMed ID: 17001346
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus.
Liu YC; Lu PL; Hsiao HH; Chang CS; Liu TC; Yang WC; Lin SF
Ann Hematol; 2012 Apr; 91(4):587-95. PubMed ID: 21997849
[TBL] [Abstract][Full Text] [Related]
17. A non-myeloablative conditioning regimen in allogeneic stem cell transplantation from related and unrelated donors in elderly patients.
Tsirigotis P; Bitan RO; Resnick IB; Samuel S; Ackerstein A; Eladì S; Gesundheit B; Zilberman I; Miron S; Leubovic A; Slavin S; Shapira MY
Haematologica; 2006 Jun; 91(6):852-5. PubMed ID: 16769592
[TBL] [Abstract][Full Text] [Related]
18. Comparable incidence and severity of cytomegalovirus infections following T cell-depleted allogeneic stem cell transplantation preceded by reduced intensity or myeloablative conditioning.
Kalpoe JS; van der Heiden PL; Vaessen N; Claas EC; Barge RM; Kroes AC
Bone Marrow Transplant; 2007 Jul; 40(2):137-43. PubMed ID: 17530007
[TBL] [Abstract][Full Text] [Related]
19. Impact of early NK cell recovery on development of GvHD and CMV reactivation in dose-reduced regimen prior to allogeneic PBSCT.
Scholl S; Mügge LO; Issa MC; Kasper C; Pachmann K; Höffken K; Sayer HG
Bone Marrow Transplant; 2005 Jan; 35(2):183-90. PubMed ID: 15531897
[TBL] [Abstract][Full Text] [Related]
20. Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients.
Iravani M; Evazi MR; Mousavi SA; Shamshiri AR; Tavakoli M; Ashouri A; Samiee S; Chahardovali B; Alimoghaddam K; Ghaffari SH; Ghavamzadeh A
Bone Marrow Transplant; 2007 Jul; 40(2):105-10. PubMed ID: 17468775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
